Waters Corp. Reports 2025 Annual Results, Details Transformative $16.8B BD Biosciences Acquisition & $4B Debt Assumption

summarizeSummary

Waters Corp. filed its 2025 annual report, detailing modest financial growth and providing extensive information on the recently closed $16.8 billion acquisition of BD's Biosciences & Diagnostic Solutions business, including $4.0 billion in assumed debt and a new segment structure.

check_boxKey Events

• 2025 Annual Financial Performance

  Waters Corporation reported a 7% increase in total net sales to $3.165 billion and a 1% rise in net income to $642.6 million for the fiscal year ended December 31, 2025. Diluted EPS saw a slight increase to $10.76, while operating income decreased by 3% due to acquisition-related and ERP implementation costs.

• Transformative Acquisition of BD Biosciences & Diagnostic Solutions

  The company completed the acquisition of BD's Biosciences & Diagnostic Solutions business on February 9, 2026, for a total purchase price of $16.8 billion, including $4.0 billion in assumed debt. This acquisition is described as a 'transformative combination' establishing a global leader in life sciences and diagnostics.

• Significant Debt Assumption and Refinancing Plans

  As a result of the BD Biosciences acquisition, Waters assumed $4.0 billion in unsecured term loans. The company plans to refinance a $3.5 billion tranche of this debt with long-term bond financing in Q1 2026 and repay the remaining $500 million tranche prior to maturity.

• New Business Segment Reorganization

  Following the acquisition, Waters Corporation has reorganized its business into four new segments: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials Sciences, reflecting its expanded capabilities and market presence.

auto_awesomeAnalysis

This annual 10-K filing provides a comprehensive overview of Waters Corporation's financial performance for 2025 and critical details regarding its recently closed, transformative acquisition of BD's Biosciences & Diagnostic Solutions business. While 2025 saw modest revenue and net income growth, the filing highlights the significant strategic shift resulting from the $16.8 billion acquisition, which closed on February 9, 2026, as a subsequent event. The company assumed $4.0 billion in new indebtedness as part of this deal, with plans to refinance a substantial portion in Q1 2026. This report is crucial for investors to understand the company's new financial structure, expanded market presence, and the associated integration and debt management risks. The reorganization into four new segments post-acquisition also signals a significant operational change.